SwitzerReport

Independent. Trusted. Proven.

Reports

Browse current and previous editions of Switzer Report

Switzer on Saturday, 9 November 2024
Peter Switzer

We were trumped but markets liked it

Peter Switzer · November 9, 2024

Elon Musk’s support for Donald Trump, which coincided with a good sales report for the carmaker, looked like one of the best punts of all time by a hi-tech entrepreneur!

Switzer on Saturday Premium
Thursday Edition, 7 November 2024
Paul Rickard

Questions of the Week

Paul Rickard · November 7, 2024

If I based my SMSF on investing in ETFs, how much would I allocate to each asset class? What is your view on Ramsay Health Care - is it a buy, or one to leave with the keeper? What do the brokers think Of Macquarie Group? What is the last day to buy NAB shares and get the latest fully franked dividend of 85c?

Q&A Premium
Monday Edition, 4 November 2024
James Dunn

Let’s take a look at Atlassian

James Dunn · November 4, 2024

Like a number of similar companies, Atlassian has huge total addressable markets to grow into, and large material upside possible. Here’s my view on this company listed on the NASDAQ but founded by two Australians.

Investing Premium
S

SwitzerTV Monday 4th November 2024

SwitzerTV · November 4, 2024

Will a Trump victory help or hurt stocks? Meet Ryan Quinn of WQG and WCMQ which was up over 31% in the year to September and have returned over 13% p.a. since inception. How come?

Video Premium
Switzer on Saturday, 2 November 2024
Thursday Edition, 31 October 2024
Maureen Jordan

“HOT” stock: Clarity Pharmaceuticals (CU6)

Maureen Jordan · October 31, 2024

In our “HOT” stock column, Michael Gable, Managing Director of Fairmont Equities, explains why he expect Clarity Pharmaceuticals (CU6) to continue trending higher from here and current levels are a buying opportunity.

Investing Premium
1 43 44 45 46 47 109

You don't have credit card details available. You will be redirected to update payment method page. Click OK to continue.